Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Oct;132(1):30-8.
doi: 10.1016/j.pharmthera.2011.05.005. Epub 2011 May 18.

The interaction between HCV and nuclear receptor-mediated pathways

Zoe Raglow  1 , Carly Thoma-Perry, Richard Gilroy, Yu-Jui Yvonne Wan
Affiliations
Review

The interaction between HCV and nuclear receptor-mediated pathways

Zoe Raglow et al. Pharmacol Ther. 2011 Oct.

Abstract

Hepatitis C virus (HCV) is presently the leading indication for liver transplantation in Western countries. Treatment for HCV infection includes a combination of pegylated interferon and ribavirin, which produces highly variable response rates. This reflects the lack of information regarding the roles of host and viral components during viral pathogenesis. Vital processes regulated by the liver, including metabolism, lipid homeostasis, cellular proliferation, and the immune response, are known to be systematically dysregulated as a result of persistent HCV infection. Nuclear receptors and their ligands are recognized as indispensable regulators of liver homeostasis. Pathways mediated by the nuclear receptor superfamily have been shown to be profoundly disrupted during HCV infection, leading to an increased importance in elucidating the exact nature of this complex relationship. Expanded understanding of the role of nuclear receptors in HCV infection may therefore be an essential step in the search for a more universally effective treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Nuclear receptor control of lipid homeostasis in the hepatocyte
PPAR-controlled fatty acid transporters CD36 and FATP import fatty acids into the hepatocyte (Motojima, 1998). These fatty acids can then be stored as triglycerides or undergo ω- or β-oxidation, principally controlled by PPARα (Reddy, 2001). Inhibition of the PPARα pathway can lead to steatosis. LXR induces lipogenic transcription factor SREBP-1c, which acts by up regulating lipogenic genes including FAS, ACC, and SCD-1 (Lima-Cabello, 2010). PPARγ also induces these genes (Gavrilova, 2003; S. Yu, 2003). PXR promotes lipogenesis through inhibition of PPARα and activation of PPARγ (Zhou, 2006). FXR inhibits lipogenesis through SHP induction, which blocks LXR. SHP also inhibits CYP7A1, the rate-limiting enzyme for the formation of bile acids (Gadaleta, 2010). ACC, acyl-coA carboxylase; AOX, acyl-coA oxidase ;CPT-1, carnitine palmitoyl transferase 1; CYP4A1, cytochrome P450 4A1; CYP7A1, cholesterol 7α-hydroxylase; FAS, fatty acid synthase; FATP, fatty acid transport protein; FXR, farnesoid X receptor; LXR, liver X receptor; PPAR, peroxisome proliferator activated receptor; PXR, pregnane X receptor; SCD-1, stearyl-coA dehydrogenase; SHP, small heterodimer partner; SREBP-1c, steroid regulatory element-binding protein.
Figure 2
Figure 2. Nuclear receptors and the pathogenesis of HCV
Nuclear receptor-mediated pathways influence the progression of HCV-induced chronic hepatitis. HCV infection can lead to (1) inflammation, (2) steatosis, (3) steatohepatitis, (4) fibrosis, (5) cirrhosis, and (6) HCC. Depending on the model used, conflicting results were obtained. For example, PPARα can either promote or prohibit viral replication (Lyn, 2009; Nishimura-Sakurai, 2010; Rakic, 2006; Tanaka, 2008a; Tanaka, 2008b). Some of the findings have only been found in animal or cell line models (*). Please see Table 1 for details. Depending on the stage of the disease and the cell type involved, activation of nuclear receptors can either inhibit or promote the pathogenic process. For example, activation of PPARγ and LXR favors steatosis (Moriishi, 2007; Yasui, 2010) but inhibits fibrosis (Beaven, 2010; Zhao, 2006), and activation of FXR favors viral replication (Chang, 2007) but may have anti-inflammatory and anti-fibrotic effects (Fiorucci, 2004; Fiorucci, 2005; Zhang, 2009). This complicated scheme makes treatment challenging and stage-specific treatment strategies may have to be considered. FXR, farnesoid X receptor; LXR, liver X receptor; PPAR, peroxisome proliferator activated receptor; RXR, retinoid X receptor; SHP, small heterodimer partner.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abdalla MY, Ahmad IM, Spitz DR, Schmidt WN, Britigan BE. Hepatitis C virus-core and non structural proteins lead to different effects on cellular antioxidant defenses. J Med Virol. 2005;76:489–497. - PubMed
    1. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358–1364. - PubMed
    1. Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology. 2006;44:527–535. - PubMed
    1. Beaven SW, Wroblewski K, Wang J, Hong C, Bensinger S, Tsukamoto H, Tontonoz P. Liver X Receptor Signaling is a Determinant of Stellate Cell Activation and Susceptibility to Fibrotic Liver Disease. Gastroenterology. 2010 - PMC - PubMed
    1. Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV, Verma IM. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest. 2010;120:924–930. - PMC - PubMed

Publication types

Substances